A Biodegradable Polymer Is Moving Into U.S. Nerve Repair Surgery
A French startup called Tissium is bringing a new surgical material into U.S. operating rooms with the goal of improving how damaged peripheral nerves are repaired. Instead of relying only on delicate microsutures to align severed nerves, the company has developed a thick liquid biopolymer that adheres to tissue when exposed to light, temporarily holding nerve ends in place while the body heals.
The approach targets a difficult and common clinical problem. According to the company’s account in a Wired report, roughly 500,000 Americans experience nerve injuries that require treatment each year. Many of those injuries involve cuts to peripheral nerves in the hands or fingers, where a successful repair can make the difference between restored sensation and long-term numbness, tingling, or sharp pain.
Peripheral nerves branch out from the brain and spinal cord to the rest of the body. When one of those nerves is cut, the two ends need to be aligned and stabilized so the tissue can slowly reconnect. That sounds straightforward in principle, but in practice it is a microsurgical task that demands precision. If the ends are not held correctly, recovery can be incomplete and symptoms can persist long after the initial injury has healed.
Tissium’s answer is to supplement or replace some traditional stitching with a light-activated liquid that behaves like a temporary splint. The material is made from fatty acid and glycerol, both of which naturally occur in the body. Once applied and exposed to light, it bonds to tissue and helps keep the nerve in place. Over time, the material biodegrades, ideally disappearing after its job is done.
Why Surgeons Are Interested in an Alternative to Microsutures
The pitch is not that surgery becomes simple. It is that one especially demanding part of the repair could become more consistent and less traumatic. Maria Pereira, Tissium’s cofounder and deputy chief executive officer, told Wired that the company is trying to provide a better way for peripheral nerves to be repaired in a consistent manner, with less trauma and better patient outcomes.
That consistency matters because peripheral nerve repair is often performed in small anatomical spaces and under time pressure after an injury. Conventional microsutures remain standard, but they are technically exacting and can place mechanical stress on already damaged tissue. A material that secures alignment without requiring the same amount of stitching could potentially reduce handling of the nerve while still providing the stability needed for regeneration.
The company has already tested the technology in a small U.S. trial involving 12 patients with injured finger nerves. In that group, all 12 regained the ability to feel temperature, pain, texture, and light touch in their fingers. Wired reported that this compared with a little over 80 percent recovery using other techniques. The report also said that none of the patients described pain or device-related complications one year later.
Those numbers are encouraging, but they also require careful interpretation. A 12-patient study is a limited sample, and the article itself notes that further evidence is needed. Early clinical signals can show promise without settling how well a treatment will perform across larger and more varied patient populations. That is especially true in surgery, where outcomes can depend on the type of injury, timing of treatment, surgeon technique, and the anatomy involved.
From Experimental Material to Commercial Product
Even so, the transition from trial results to real-world availability is already underway. The treatment is available for surgeons to purchase in the United States, which means Tissium is no longer operating purely in the research stage. That shift from concept to commercialization is one reason the story matters beyond a single device. Regenerative medicine often produces promising lab results that struggle to become practical tools. Here, a biomaterial has moved far enough along that surgeons can actually decide whether to use it.
The startup is also raising capital to support that expansion. Tissium told Wired it has raised 30 million euros in private investment from venture capital firms and family offices, along with 30 million euros in debt financing from the European Investment Bank. The company plans to continue manufacturing its product in France while scaling commercialization.
That financing mix is significant because medical devices that change surgical workflow typically require more than strong science. They need manufacturing reliability, regulatory progress, surgeon training, and enough capital to sustain adoption over time. A material that appears simple at the bedside can still be operationally difficult to scale unless production, handling, and clinical support are tightly managed.
External experts appear interested but measured. Simran Chana, a surgeon, materials scientist, and director of the Frontier Technologies Laboratory at the University of Cambridge, told Wired that it is exciting to see more advanced biomaterials and regenerative medical techniques become available to surgeons, while also emphasizing the need for further evidence. That is a sensible place to land. The promise here lies in making a fragile repair more reproducible, but medicine usually demands broader validation before early gains translate into a new standard of care.
What This Could Mean for Nerve Repair
If larger studies support the early findings, Tissium’s polymer could represent a meaningful refinement in how peripheral nerve injuries are treated. The main advantage would not necessarily be replacing every suture in every case. It could be reducing the burden of one of the most delicate parts of the operation while preserving the conditions needed for the nerve to recover function.
That matters because the consequences of incomplete nerve healing are deeply practical. Loss of light touch, altered pain sensation, and reduced dexterity can reshape a patient’s ability to work, cook, write, or simply use a hand normally. Incremental improvements in surgical repair therefore carry outsized quality-of-life value.
For now, the strongest conclusion is narrower. Tissium has developed a biodegradable, light-activated polymer for peripheral nerve repair, shown positive early results in a small U.S. study, and begun commercial deployment with surgeons in the United States. In a field where small technical improvements can have large human effects, that is enough to make the technology worth watching closely.
This article is based on reporting by Wired. Read the original article.
Originally published on wired.com
